AgamiR., BernardsR.: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage.Cell, 102: 55–66, 2000.
2.
HainautP., HernandezT., RobinsonA.: IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools.Nucleic Acids Res, 26: 205–213, 1998.
3.
CahillD.P., LengauerC., YuJ.: Mutations of mitotic checkpoint genes in human cancers.Nature, 392: 300–303, 1998.
4.
IsolaJ., VisakorpiT., HolliK.: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.J Natl Cancer Inst, 84: 1109–1114, 1992.
5.
SilvestriniR., BeniniE., DaidoneM.G.: p53 as an independent prognostic marker in lymph node-negative breast cancer patients.J Natl Cancer Inst, 85: 965–970, 1993.
6.
O'ConnorP.M., JackmanJ., BaeI.: Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.Cancer Res, 57: 4285–4300, 1997.
7.
BurkeH.B., HoangA., IglehartJ.D.: Predicting response to adjuvant and radiation therapy in patients with early stage carcinoma.Cancer, 82: 874–877, 1998.
8.
ThorA.D., MooreD.H.I., EdgertonS.M.: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.J Natl Cancer Inst, 84: 845–855, 1992.
9.
BianchiS., CalzolariA., VazzosiV.: Lack of prognostic value of p53 protein expression in node-negative breast cancer.Tumori, 83: 669–672, 1997.
10.
AhrendtS.A., HalachmiS., ChowJ.T.: Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array.Proc. Natl Acad Sci USA, 96: 7382–7387, 1999.
11.
WenW.H., BernsteinL., LescallettJ.: Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis.Cancer Res, 60: 2716–2722, 2000.
12.
BaldinV., LukasJ., MarcoteM.J.: Cyclin D1 is a nuclear protein required for cell cycle progression in G1.Genes Dev, 7: 812–821, 1993.
13.
PelosioP., BarbareschiM., BonoldiE.: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy.Ann Oncol, 7: 695–703, 1996.
14.
Weinstat-SaslowD., MerinoM.J., ManrowR.E.: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.Nat Med, 1: 1257–1260, 1995.
15.
PorterP.L., MaloneK.E., HeagertyP.J.: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.Nat Med, 3: 222–225, 1997.
16.
HunterT., PinesJ.Cyclins and cancer.Cell, 66: 1071–1074, 1991.
17.
CairnsP., PolascikT.J., EbyY.: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors.Nat Genet, 11: 210–212, 1995.
18.
CatzavelosC., BhattacharyaN., UngY.C.: Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer.Nat Med, 3: 227–230, 1997.
19.
Duenas-GonzalezA., Abad-HernandezM.M., Cruz-HernandezJ.J.: Analysis of bcl-2 in sporadic breast carcinoma.Cancer, 80: 2100–2108, 1997.
20.
BerardoM.D., ElledgeR.M., De MoorC.: Bcl-2 and apoptosis in lymph node positive breast carcinoma.Cancer, 82: 1296–1302, 1998.
21.
SilvestriniR., DaidoneM.G., LuisiA.: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer.J Clin Oncol, 13: 697–704, 1995.
22.
FitzgibbonsP.L., PageD.L., WeaverD.: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.Arch Pathol Lab Med, 124: 966–978, 2000.
23.
De PotterC.R., SchelfhoutA.M.: The neu-protein and breast cancer.Virchows Arch, 426: 107–115, 1995.
24.
KallioniemiO.P., HolliK., ViskorpiT.: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.Int J Cancer, 49: 650–655, 1991.
25.
MussH.B., ThorA.D., BerryD.A.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.N Engl J Med, 330: 1260–1266, 1994.
26.
ToikkanenS., HelinH., IsolaJ.: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.J Clin Oncol, 10: 1044–1048, 1992.
27.
SimonR., NocitoA., HubscherT.: Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer.J Natl Cancer Inst, 93: 1141–1146, 2001.
RipaniE., SacchettiA., CordaD.: The human Trop-2 is a tumor-associated calcium signal transducer.Int J Cancer, 76: 671–676, 1998.
30.
GastlG., SpizzoG., ObristP.: Ep-CAM overexpression in breast cancer as a predictor of survival.Lancet, 356: 1981–1982, 2000.
31.
AhmadA., HanbyA., DublinE.: Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression.Am J Pathol, 152: 721–728, 1998.
32.
MassonR., LefebvreO., NoelA.: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy.J Cell Biol, 140: 1535–1541, 1998.
33.
BassetG., BellocqJ.P., WolfC.: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas.Nature, 348: 699–704, 1990.
34.
IsolaJ., WeitzS., VisakorpiT.: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.J Clin Oncol, 11: 36–43, 1993.
35.
DomagalaW., StrikerG., SzadowskaA.: Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.Am J Pathol, 141: 1003–1012, 1992.
36.
PykeC., KristensenP., RalfkiaerE.: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.Am J Pathol, 138: 1059–1067, 1991.
37.
ReillyD., AndreasenP.A., DuffyM.J.: Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.Blood Coagul. Fibrinolysis, 2: 47–50, 1991.
38.
MignattiP., RifkinD.B.: Biology and biochemistry of proteinases in tumor invasion.Physiol Rev, 73: 161–195, 1993.
39.
VarleyJ.M., SwallowJ.E., BrammarW.J.: Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.Oncogene, 1: 423–430, 1987.
40.
BorgA., SigurdssonH., ClarkG.M.: Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.Br J Cancer, 63: 136–142, 1991.
41.
GillettC., FantlV., SmithR.: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.Cancer Res, 54: 1812–1817, 1994.
42.
TsudaH., HirohashiS., ShimosatoY.: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.Cancer Res, 49: 3104–3108, 1989.
43.
T'AngA., VarleyJ.M., ChakrabortyS.: Structural rearrangement of the retinoblastoma gene in human breast carcinoma.Science, 242: 263–266, 1988.
44.
Von LintigF.C., DreilingerA.D., VarkiN.M.: Ras activation in human breast cancer.Breast Cancer Res Treat, 62: 51–62, 2000.
45.
SchondorfT., AndrackA., NiederacherD.: H-ras gene amplification or mutation is not common in human primary breast cancer.Oncol Rep, 6: 1029–1033, 1999.
46.
McGuireW.L.: Breast cancer prognostic factors: evaluation guidelines.J Natl Cancer Inst, 83: 154–155, 1991.
47.
AlonU., BarkaiN., NottermanD.A.: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays.Proc Natl Acad Sci USA, 96: 6745–6750, 1999.
48.
ErmolaevaO., RastogiM., PruittK.D.: Data management and analysis for gene expression arrays.Nat Genet, 20: 19–23, 1998.
49.
IyerV.R., EisenM.B., RossD.T.: The transcriptional program in the response of human fibroblasts to serum.Science, 283: 83–87, 1999.
50.
PerouC.M., JeffreyS.S., Van de RijnM.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.Proc Natl Acad Sci USA, 96: 9212–9217, 1999.
51.
PerouC.M., SorlieT., EisenM.B.: Molecular portraits of human breast tumours.Nature, 406: 747–752, 2000.
52.
KudohK., RamannaM., RavatnR.: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray.Cancer Res, 60: 4161–4166, 2000.
53.
BlackstockW.P., WeirM.P.: Proteomics: quantitative and physical mapping of cellular proteins.Trends Biotechnol, 17: 121–127, 1999.
54.
WilkinsM.R., GasteigerE., GooleyA.A.: High-throughput mass spectrometric discovery of protein post- translational modifications.J Mol Biol, 289: 645–657, 1999.
